Free Trial
→ How to claim a stake in SpaceX before the June 12 IPO (From Brownstone Research) (Ad)tc pixel
NYSEAMERICAN:AIM

AIM ImmunoTech Q3 2025 Earnings Report

AIM ImmunoTech logo
$0.52 -0.08 (-12.77%)
Closing price 06/5/2026 04:10 PM Eastern
Extended Trading
$0.51 -0.01 (-1.90%)
As of 06/5/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

AIM ImmunoTech EPS Results

Actual EPS
-$1.57
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

AIM ImmunoTech Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AIM ImmunoTech Announcement Details

Quarter
Q3 2025
Date
11/17/2025
Time
Before Market Opens
Conference Call Date
Monday, November 17, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

AIM ImmunoTech's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

AIM ImmunoTech Earnings Headlines

AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness
June 4 at 3:24 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/aim-immunotech-releases-virtual-investor-what-this-means-video-segment-discussing-ampligen-s-potential-in-ebola-virus-disease-preparedness-1036225068
AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcript
June 4 at 12:01 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4912000-aim-immunotech-inc-aim-discusses-ampligens-potential-role-in-addressing-bundibugyo-ebola
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
June 6 at 1:00 AM  |  Porter & Company (Ad)
AIM ImmunoTech Releases Virtual Investor ‘What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparedness
June 4 at 9:03 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3306779/29489/en/AIM-ImmunoTech-Releases-Virtual-Investor-What-This-Means-Video-Segment-Discussing-Ampligen-s-Potential-in-Ebola-Virus-Disease-Preparedness.html
AIM stock soars 42% as pancreatic cancer trial hits key enrollment milestone before schedule — CEO sees 'significant value-inflection period' ahead
June 1, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/aim-stock-soars-42-as-pancreatic-cancer-trial-hits-key-enrollment-milestone-before-schedule-ceo-sees-significant-value-inflection-period-ahead/ar-AA24ze3F
AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead
June 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/aim-stock-soars-42-pancreatic-141922813.html
See More AIM ImmunoTech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AIM ImmunoTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AIM ImmunoTech and other key companies, straight to your email.

About AIM ImmunoTech

AIM ImmunoTech (NYSEAMERICAN:AIM) is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats. AIM ImmunoTech has collaborated with government agencies and academic institutions to support its clinical development, leveraging these partnerships to access specialized expertise and streamline regulatory pathways.

Headquartered in Ocala, Florida, AIM ImmunoTech conducts its research and manufacturing operations in the United States, while seeking to establish strategic collaborations that extend its global reach. The company’s management team comprises experienced professionals in biotechnology development, regulatory affairs and commercial strategy, with a shared commitment to bringing novel immunotherapeutic solutions to market.

View AIM ImmunoTech Profile
Earnings Tools